The Claim
The FT3/FT4 ratio at diagnosis in children with Graves' disease does not reliably predict sustained remission after antithyroid drug therapy.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In children diagnosed with Graves' disease, the ratio of free triiodothyronine to free thyroxine at the time of diagnosis does not accurately identify which children will achieve long-term remission after treatment with antithyroid drugs.
See the scientific wording
In children with Graves' disease, the FT3/FT4 ratio at diagnosis does not reliably predict sustained remission after antithyroid drug therapy, indicating that this biomarker is not useful for identifying patients likely to achieve long-term remission.
At diagnosis, the ratio of two thyroid hormones shows how active the thyroid gland is right then, but it does not show whether the immune system will keep attacking the gland after treatment stops. The immune system keeps driving the disease regardless of how high the hormone levels are at the start.
What the research says
1 studyStudy: The role of the FT3/FT4 ratio in predicting remission and relapse in pediatric Graves’ disease
The study found that checking the ratio of two thyroid hormones at diagnosis doesn't help tell if a child will stay healthy after stopping medicine, which matches the claim. But it does help predict if they might get sick again.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.